IAWG members are addressing sexual and reproductive rights during COVID-19 humanitarian response. Read More>>

Unit 4: Medications for Medical Abortion and Postabortion Care

Overview

This unit explains eligibility requirements and contraindications for medical abortion and postabortion care with mifepristone and/or misoprostol; recommended medication regimens; expected effects, side effects, warning signs, potential complications, and complications management; and post-procedure care and follow-up.

Objectives

By the end of this unit, participants will be able to:

  • Describe eligibility requirements and contraindications for medical abortion and postabortion care with mifepristone and/or misoprostol.
  • Explain recommended mifepristone and/or misoprostol regimens.
  • Explain the essential information to be given to women having uterine evacuation with mifepristone and/or misoprostol.
  • Explain the expected effects, side effects, and warning signs of uterine evacuation with mifepristone and/or misoprostol.
  • Describe potential complications of uterine evacuation with mifepristone and/or misoprostol, and complications management.
  • Describe post-procedure care and follow-up for uterine evacuation with mifepristone and/or misoprostol.

Timing & Methodology

Total: 175 minutes (2 hours 55 minutes)

  • 75 minutes: Facilitator Presentation and Group Discussion
  • 60 minutes: Demonstration and Role Plays
  • 10 minutes: Facilitator Presentation and Group Discussion
  • 10 minutes: Small Group Work: Case Study
  • 20 minutes: Facilitator Presentation and Group Discussion

Preparation

  • Print, download, and gather materials
  • Prepare flip chart pages for the Identifying and Managing Complications of Uterine Evacuation with Medications activity

Resources Available Online

Sexual and reproductive health services remain critical during COVID-19

IAWG members and partners are producing clinical and programmatic guidance, assessments, policy papers, and statements to ensure continued prioritization of sexual and reproductive health and rights throughout COVID-19 response in humanitarian settings.